Pharsight

Vyndamax generic

Vyndamax is a drug owned by Foldrx Pharms and was first authorized for market use on 3rd May, 2019. It contains the active ingredient tafamidis and is available in capsule;oral dosage forms.

When will Vyndamax generic be available?

The generic version of Vyndamax is expected to be released after 31st August, 2035. This is due to the expiration of the drug's last patent entitled 'Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole' with a US patent number of US9770441.

Vyndamax uses

Vyndamax, containing the active ingredient tafamidis, is used for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).

Vyndamax patent expiration

Vyndamax holds a total of 3 drug patents. None of these have expired yet with the last one, US9770441, set to expire on 31st August, 2035. This patent is titled 'Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole'. Other patents include US7214696 and US7214695, both titled 'Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding', and expiring on 19th December, 2024. Below are the details of the patent:

Vyndamax dosage

Want to ask something?